Telisotuzumab Vedotin: First Approval.

IF 14.4 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drugs Pub Date : 2025-09-01 Epub Date: 2025-07-30 DOI:10.1007/s40265-025-02210-z

Hannah A Blair

引用次数: 0

Abstract

Telisotuzumab vedotin (telisotuzumab vedotin-tllv; EMRELIS^™), an antibody-drug conjugate (ADC) directed against c-mesenchymal-epithelial transition factor (c-MET) protein, is being developed by AbbVie for the treatment of solid tumours. On 14 May 2025, telisotuzumab vedotin received accelerated approval in the USA for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, as determined by an FDA-approved test, who have received a prior systemic therapy. This article summarizes the milestones in the development of telisotuzumab vedotin leading to this first approval for NSCLC.

查看原文本刊更多论文

Telisotuzumab Vedotin：首次批准。

Telisotuzumab vedotin (Telisotuzumab vedotin-tllv；EMRELIS™是一种针对c-间充质上皮转化因子（c-MET）蛋白的抗体-药物偶联物（ADC），由艾伯维公司（AbbVie）开发，用于治疗实体肿瘤。2025年5月14日，telisotuzumab vedotin在美国获得加速批准，用于治疗局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）高c-Met蛋白过表达的成年患者，该患者先前接受过全身治疗，经fda批准的测试确定。本文总结了telisotuzumab vedotin首次获批用于非小细胞肺癌的发展里程碑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs 医学-毒理学

CiteScore

22.70

自引率

0.90%

发文量

134

审稿时长

3-8 weeks

期刊介绍： Drugs is a journal that aims to enhance pharmacotherapy by publishing review and original research articles on key aspects of clinical pharmacology and therapeutics. The journal includes: Leading/current opinion articles providing an overview of contentious or emerging issues. Definitive reviews of drugs and drug classes, and their place in disease management. Therapy in Practice articles including recommendations for specific clinical situations. High-quality, well designed, original clinical research. Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs. AdisInsight Reports summarising development at first global approval. Moreover, the journal offers additional digital features such as animated abstracts, video abstracts, instructional videos, and podcasts to increase visibility and educational value. Plain language summaries accompany articles to assist readers with some knowledge of the field in understanding important medical advances.